

Quarterly Disclosure Statements
(Unaudited)
For the Nine Months Ended September 30, 2024
For



Advocate Aurora Health, Inc.



The Charlotte-Mecklenburg Hospital Authority
Combined Group



Wake Forest Baptist Combined Group

Investor Relations Contact:
Jenny Temple, VP Treasury and Assistant Treasurer
Email: jennifer.temple@atriumhealth.org

ADVOCATE HEALTH, INC. TABLE OF CONTENTS

INTRODUCTION:	2
ADVOCATE HEALTH:	
<u>Introduction</u>	<u>3</u>
Combined Balance Sheets	<u>4</u>
Combined Statements of Operations and Changes in Net Assets	<u>5</u>
Combined Statements of Cash Flows	<u>7</u>
<u>Utilization Statistics and Key Financial Ratios</u>	<u>8</u>
Other Financial Information	<u>9</u>
ADVOCATE AURORA HEALTH, INC:	
<u>Introduction</u>	<u>10</u>
Consolidated Financial Statements	<u>11</u>
<u>Utilization Statistics and Sources of Revenue</u>	<u>16</u>
THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH COMBINED GROUP:)
<u>Introduction</u>	<u>17</u>
<u>Financial Highlights</u>	<u>18</u>
Combined Financial Statements	<u>19</u>
<u>Utilization Statistics</u>	<u>22</u>
ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED GROUP:	
Introduction	<u>23</u>
Combined Financial Statements	<u>24</u>
Combining Financial Statements	<u>28</u>
<u>Utilization Statistics</u>	<u>31</u>

Introduction

Purpose of this Report

The purpose of this report is to provide information necessary to comply with continuing disclosure undertakings for the Advocate Aurora Health Credit Group, The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health Combined Group and the Atrium Health Wake Forest Baptist Combined Group, as described below, all of which are now part of an integrated health care delivery and academic system known as Advocate Health.

Advocate Health

Advocate Aurora Health, Inc., a Delaware nonprofit nonstock corporation ("AAH") and Atrium Health, Inc., a North Carolina nonprofit corporation ("AHI"), entered into a Joint Operating Agreement pursuant to which they created Advocate Health, Inc., a Delaware nonprofit nonstock corporation (the "Advocate Health JOC"), to manage and oversee Advocate Health, which focuses on meeting patients' needs by redefining how, when and where care is delivered. AAH and AHI are the two corporate members of the Advocate Health JOC. AAH and the entities comprising the "AAH System" described below (the "AAH System Entities") and AHI and the other participants in the "AHI Enterprise" described below (the "AHI Enterprise Entities") have maintained their separate legal existence and no sale, transfer or other conveyance of their assets occurred in connection with the formation of Advocate Health. No assumption or guaranty of debt or other liabilities of the AAH System Entities or AHI Enterprise Entities, or changes to their respective credit groups described below, occurred in connection with the formation of Advocate Health. Advocate Health has a combined footprint across Illinois, Wisconsin, North Carolina, South Carolina, Georgia and Alabama.

Advocate Aurora Health, Inc.

AAH is the sole corporate member of Advocate Health Care Network, an Illinois not for profit corporation, ("Advocate") and Aurora Health Care, Inc., a Wisconsin nonstock not-for-profit corporation ("Aurora"). AAH, Advocate, Aurora and their controlled subsidiaries are collectively referred to herein as the "AAH System." The AAH System serves patients across northern and central Illinois and eastern Wisconsin. The participants in the AAH System do business as Advocate in Illinois and as Aurora in Wisconsin.

Atrium Health, Inc.

The Charlotte-Mecklenburg Hospital Authority ("CMHA" or "Atrium Health CMHA"), which directly and through its affiliates does business as Atrium Health, and the Wake Forest Baptist Health system ("Wake Forest Baptist" or "Atrium Health Wake Forest Baptist), including Wake Forest School of Medicine, are part of a single enterprise (the "AHI Enterprise"), governed and managed by AHI pursuant to a health system integration agreement and related agreements. The AHI Enterprise serves patients across North Carolina, South Carolina, Georgia and Alabama. The participants in the AHI Enterprise do business as Atrium Health and Atrium Health Wake Forest Baptist (in North Carolina and South Carolina) and as Atrium Health Navicent and Atrium Health Floyd (in Georgia and Alabama).



Advocate Health

The financial position and results of operation of Advocate Health are presented by combining the financial statements of AAH, Atrium Health CMHA and Atrium Health Wake Forest Baptist, which are under the common management of the Advocate Health JOC. Advocate Health, which includes Atrium Health CMHA, has prepared its financial statements in accordance with accounting principles as promulgated by the Financial Accounting Standards Board ("FASB"). Atrium Health CMHA is a governmental entity as defined by the Governmental Accounting Standards Board ("GASB"); accordingly, accounting principles as promulgated by GASB are the appropriate accounting principles for Atrium Health CMHA to follow. Preparation of the Advocate Health combined financial statements requires the financial statements of Atrium Health CMHA to be converted from presentation in accordance with GASB accounting principles to presentation in accordance with FASB accounting principles prior to combination.

The Advocate Health combined financial statements are not required to be delivered pursuant to any continuing disclosure undertaking and are being provided on a voluntary basis.

ADVOCATE HEALTH COMBINED BALANCE SHEETS - FASB

	September 30, 2024	December 31, 2023		
Assets				
Current assets				
Cash and cash equivalents	\$ 2,284,087	\$ 2,260,650		
Short term investments	48,871	38,960		
Assets limited as to use	184,545	232,844		
Patient accounts receivable	3,900,123	3,770,804		
Other current assets	2,394,024	1,986,633		
Total current assets	8,811,650	8,289,891		
Other assets				
Assets limited as to use	23,508,862	21,255,434		
Property and equipment, net	13,174,234	12,605,078		
Operating lease right-of-use assets	1,034,626	997,099		
Other noncurrent assets	1,312,201	1,470,383		
Total other assets	39,029,923	36,327,994		
Total assets	\$ 47,841,573	\$ 44,617,885		
Liabilities				
Current liabilities				
Long-term debt, current portion	\$ 1,063,143	\$ 1,247,479		
Operating lease liabilities, current portion	194,913	185,955		
Accrued salaries and employee benefits	2,190,629	2,366,585		
Accounts payable and other accrued liabilities	3,200,636	2,691,445		
Third-party payors payables	894,836	805,721		
Total current liabilities	7,544,157	7,297,185		
Noncurrent liabilities				
Long-term debt, less current portion	6,668,656	6,514,016		
Operating lease liabilities, less current portion	922,157	888,095		
Obligations under swap agreements	126,753	122,271		
Other noncurrent liabilities	3,302,975	3,303,141		
Total noncurrent liabilities	11,020,541	10,827,523		
Total liabilities	18,564,698	18,124,708		
Net assets				
Without donor restrictions				
Controlling interest	27,728,814	25,052,618		
Noncontrolling interests in subsidiaries	207,457	202,324		
Total net assets without donor restrictions	27,936,271	25,254,942		
With donor restrictions	1,340,604	1,238,235		
Total net assets	29,276,875	26,493,177		
Total liabilities and net assets	\$ 47,841,573	\$ 44,617,885		

ADVOCATE HEALTH COMBINED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS - FASB

	Nine Months Ended September 30, 2024		Nine Months Ended September 30, 2023	
Revenue	 i		<u> </u>	
Patient service revenue	\$ 21,595,491	\$	19,254,943	
Capitation revenue	893,359		915,363	
Other revenue	3,282,417		2,660,077	
Total revenue	 25,771,267		22,830,383	
Expenses				
Salaries, wages and benefits	14,194,367		13,274,728	
Supplies and drugs	5,465,377		4,654,253	
Purchased services and other expenses	4,033,909		3,693,645	
Depreciation and amortization	911,939		906,714	
Interest	201,491		221,624	
Total expenses	 24,807,083		22,750,964	
Operating income	964,184		79,419	
Nonoperating income				
Investment income, net	1,794,746		625,699	
Other nonoperating (loss) income, net	(43,909)		60,088	
Total nonoperating income, net	1,750,837		685,787	
Revenue in excess of expenses	2,715,021		765,206	
Less income attributable to noncontrolling interests	 (51,119)		(44,036)	
Revenue in excess of expenses - attributable to controlling interest	\$ 2,663,902	\$	721,170	

ADVOCATE HEALTH

COMBINED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS - FASB

	Nine Months Ended September 30, 2024		Nine Months Ended September 30, 2023	
Net assets without donor restrictions, controlling interest				
Revenue in excess of expenses - attributable to controlling interest	\$	2,663,902	\$	721,170
Pension-related changes other than net periodic pension costs		6,085		20,330
Other, net		6,209		14,194
Increase in net assets without donor restrictions, controlling interest		2,676,196		755,694
Net assets without donor restrictions, noncontrolling interests				
Revenues in excess of expenses		51,119		44,036
Distributions to noncontrolling interests		(45,986)		(30,353)
Increase in net assets without donor restrictions, noncontrolling interests		5,133		13,683
Net assets with donor restrictions				
Contributions		137,384		121,456
Investment income, net		64,082		24,378
Net assets released from restrictions		(106,956)		(112,272)
Other, net		7,859		130
Increase in net assets with donor restrictions		102,369		33,692
Increase in net assets		2,783,698		803,069
Net assets at beginning of period		26,493,177		24,295,691
Net assets at end of period	\$	29,276,875	\$	25,098,760

ADVOCATE HEALTH

COMBINED STATEMENTS OF CASH FLOWS - FASB

Increase in net asset Section		Months Ended ember 30, 2024	Nine Months Ended September 30, 2023	
Adjustments to reconcile change in net assets to net cash provided by operating activities: 897,614 907,926 Depreciation, amortization and accretion 153,928 154,539 Gain on sale of disposal group (84,511) — 9 Pension-related changes other than net periodic pension cost (6,085) (20,303) Distribution to noncontrolling interests 37,070 (140,311) Changes in operating assets and liabilities (2,244,468) (371,434) Trading securities, net (2,244,668) (170,345) Patient accounts receivable (108,838) (170,345) Third-party payors receivable and payable, net 157,450 82,335 Other assets and liabilities, net (184,668) (638,48) Net cash provided by operating activities 1,346,670 643,689 Net cash provided by operating activities (1,429,805) (997,069) Cash flows from investing activities (1,429,805) (997,069) Cash neceived from sale of disposal group 177,995 — Capital expenditures (1,429,805) (997,069) Cash received from sale of disposal group 17,095	Cash flows from operating activities			
Depreciation, amortization and accretion 897,614 907,926 Amortization of operating lease right-of-use assets 153,928 154,539 Gain on sale of disposal group (84,511) Pension-related changes other than net periodic pension cost (6,085) (20,330) Distribution to noncontrolling interests 53,310 36,488 Other (70,760) (101,311) Changes in operating assets and liabilities (2,244,468) (371,434) Patient accounts receivable (108,838) (170,455) Third-party payors receivable and payable, net (184,668) (638,248) Other assets and liabilities, net (184,668) (638,248) Third-party payors receivable and payable, net (184,668) (638,248) Other assets and liabilities, net (184,668) (638,248) Third-party payors receivable and payable, net (184,668) (638,248) Other assets and liabilities, net (184,668) (638,248) A pristion of pristing activities (1,429,805) (997,069) Cash received from isale of disposal group (17,092)	Increase in net assets	\$ 2,783,698	\$	803,069
Amortization of operating lease right-of-use assets 153,928 154,539 Gain on sale of disposal group (84,51) — 9 Pension-related changes other than net periodic pension cost (6,085) 20,330 Distribution to noncontrolling interests 53,310 36,488 Other (70,766) (140,311) Changes in operating assets and liabilities (2,244,468) (371,434) Patient accounts receivable (108,838) (170,345) Patient accounts receivable and payable, net (184,668) 6638,248 Other assets and liabilities, net (184,668) 6638,248 Net cash provided by operating activities 1,346,670 643,689 Capital expenditures (1,429,805) (997,069) Capital expenditures (1,429,805) (1,429,805)	Adjustments to reconcile change in net assets to net cash provided by operating activities:			
Gain on sale of disposal group (84,511) — Pension-related changes other than net periodic pension cost (6,085) (20,330) Distribution to noncontrolling interests 33,310 36,488 Other (70,760) (140,311) Changes in operating assets and liabilities 371,434 471,434 Patient accounts receivable (108,838) (170,345) Patient accounts receivable and payable, net 157,450 82,335 Other assets and liabilities, net (184,668) 638,248 Net cash provided by operating activities 1,346,670 643,688 Other assets and liabilities, net (1,429,805) (997,069) Cash flows from investing activities (1,429,805) (997,069) Cash received from sale of disposal group 177,995 — Acquisition of business, net of cash acquired (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Act and subsequivalents of long-term debt, net (266,623) (332,650) Proceeds from financing activities (266,623) (332,650) Proceeds from i	Depreciation, amortization and accretion	897,614		907,926
Pension-related changes other than net periodic pension cost (6,085) (20,300) Distribution to noncontrolling interests 53,310 36,488 Other (20,076) (140,311) Changes in operating assets and liabilities Trading securities, net (2,244,468) (371,434) Patient accounts receivable (108,838) (170,345) Third-party payors receivable and payable, net (184,668) 638,248 Other assets and liabilities, net (184,668) 638,248 Net cash provided by operating activities (184,668) 638,248 Net cash provided by operating activities (1,429,805) (997,069) Cash flows from investing activities (1,429,805) (997,069) Cash received from sale of disposal group 177,995 - Acquisition of business, net of cash acquired (116,706) - Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (266,623) (332,650) Proceeds from issuance of long-term debt, (266,623) (332,650)	Amortization of operating lease right-of-use assets	153,928		154,539
Distribution to noncontrolling interests 53,310 36,488 Other (70,760) (140,311) Changes in operating assets and liabilities (2,244,468) (371,434) Patient accounts receivable (108,838) (170,345) Third-party payors receivable and payable, net 157,450 82,335 Other assets and liabilities, net (134,668) (638,248) Net cash provided by operating activities 1,346,670 643,689 Cash flows from investing activities (14,29,805) (997,069) Capital expenditures (116,706) - Capital expenditures (116,706) - Capital expenditures (116,706) - Capital expenditures (14,29,805) (997,069) Cash received from sale of disposal group 177,995 - Acquisition of business, net of cash acquired (116,706) - Other 3,401 4,732,91 Net cash used in investing activities (2,66,623) (332,650) Post cash flows from financing activities (266,623) (332,650) Proceeds f	Gain on sale of disposal group	(84,511)		_
Other (70,760) (140,311) Changes in operating assets and liabilities 3(71,434) Trading securities, net (108,838) (170,345) Patient accounts receivable (108,838) (170,345) Third-party payors receivable and payable, net 157,450 82,335 Other assets and liabilities, net (184,668) (638,248) Net cash provided by operating activities 1,346,670 643,688 Capital expenditures (1,429,805) (997,069) Cash flows from investing activities 111,6706 — Capital expenditures (116,706) — Capital expenditures (116,706) — Capital expenditures (116,706) — Capital expenditures (114,799,055) (997,069) Cash flows from investing activities (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Other (34,41) 473,291 Net cash used in investing activities 2(8,474) (34,312) Repayments of long-term debt, net (26,623)	Pension-related changes other than net periodic pension cost	(6,085)		(20,330)
Changes in operating assets and liabilities (2,244,468) (371,434) Patient accounts receivable (108,838) (170,345) Third-party payors receivable and payable, net 157,450 82,335 Other assets and liabilities, net (184,668) (638,248) Net cash provided by operating activities 1,346,670 643,689 Cash flows from investing activities (1,429,805) (997,069) Cash received from sale of disposal group 177,995 - Acquisition of business, net of cash acquired (16,709) - Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (1,373,589) (568,548) Cash flows from financing activities (266,623) (332,650) Proceeds from issuance of long-term debt, net (266,623) (332,650) Proceeds from restricted contributions and income on investments (19,347) 69,954 Net cash provided by (used in) financing activities 109,247 69,954 Net cash provided by (used in) financing activities 13,201 (49,848) </td <td>Distribution to noncontrolling interests</td> <td>53,310</td> <td></td> <td>36,488</td>	Distribution to noncontrolling interests	53,310		36,488
Trading securities, net (2,244,68) (371,434) Patient accounts receivable (108,838) (170,345) Third-party payors receivable and payable, net 157,450 82,335 Other assets and liabilities, net (184,668) (638,248) Net cash provided by operating activities 1,346,670 643,689 Cash flows from investing activities (1,429,805) (997,069) Cash received from sale of disposal group 177,995 — Acquisition of business, net of cash acquired (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,201 Net cash used in investing activities (1,373,589) (568,548) Proceeds from financing activities (266,623) (332,650) Proceeds from issuance of long-term debt, net (266,623) (332,650) Proceeds from issuance of long-term debt (53,310) (36,488) Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,24 69,954 Net in	Other	(70,760)		(140,311)
Patient accounts receivable (108,838) (170,345) Third-party payors receivable and payable, net 157,450 82,335 Other assets and liabilities, net (184,668) (638,248) Net cash provided by operating activities 1,346,670 643,689 Cash flows from investing activities "Use of 1,429,805" (997,069) Cash received from sale of disposal group 177,995 — Acquisition of business, net of cash acquired (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (1,373,589) (568,548) Cash flows from financing activities (266,623) (332,650) Proceeds from issuance of long-term debt, net (266,623) (332,650) Proceeds from issuance of long-term debt 250,806 174,195 Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,247 69,954 Net increase (decrease) in cash and cash equivalents 13,201 (49,848) <	Changes in operating assets and liabilities			
Third-party payors receivable and payable, net 157,450 82,335 Other assets and liabilities, net (184,668) (638,248) Net cash provided by operating activities 1,346,670 643,689 Cash flows from investing activities Very 1,346,670 643,689 Cash flows from investing activities (1,429,805) (997,069) Cash received from sale of disposal group 177,995 - Acquisition of business, net of cash acquired (116,706) - Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (1,373,589) (568,548) Repayments of long-term debt, net (266,623) (332,650) Proceeds from issuance of long-term debt 250,806 174,195 Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,247 69,954 Net cash provided by (used in) financing activities 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 13,201 49,848	Trading securities, net	(2,244,468)		(371,434)
Other assets and liabilities, net (184,668) (638,248) Net cash provided by operating activities 1,346,670 643,689 Cash flows from investing activities Capital expenditures (1,429,805) (997,069) Cash received from sale of disposal group 177,995 — Acquisition of business, net of cash acquired (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (1,373,589) (568,548) Cash flows from financing activities Repayments of long-term debt, net (266,623) (332,650) Proceeds from issuance of long-term debt (53,310) (36,488) Proceeds from restricted contributions and income on investments (53,310) (36,488) Post cash provided by (used in) financing activities 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 3,201 49,848 Cash and cash equivalents at beginning of period 2,318,787 1,411,867 Cash and cash equivalents at end of period 2,33	Patient accounts receivable	(108,838)		(170,345)
Cash flows from investing activities (1,429,805) (997,069) Cash received from sale of disposal group 177,995 — Acquisition of business, net of cash acquired (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (1,373,589) (568,548) Cash flows from financing activities Variable of the control	Third-party payors receivable and payable, net	157,450		82,335
Cash flows from investing activities Capital expenditures (1,429,805) (997,069) Cash received from sale of disposal group 177,995 — Acquisition of business, net of cash acquired (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities *** *** Repayments of long-term debt, net (266,623) (332,650) Proceeds from issuance of long-term debt 250,806 174,195 Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,247 69,954 Net cash provided by (used in) financing activities 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 13,201 (49,848) Cash and cash equivalents at beginning of period 2,318,787 1,441,867 Cash and cash equivalents at end of period \$ 2,331,988 \$ 1,392,019 Reconciliation of cash and cash equivalents to the balance sheet 2,284,087 1,337,090 <td< td=""><td>Other assets and liabilities, net</td><td>(184,668)</td><td></td><td>(638,248)</td></td<>	Other assets and liabilities, net	(184,668)		(638,248)
Capital expenditures (1,429,805) (997,069) Cash received from sale of disposal group 177,995 — Acquisition of business, net of cash acquired (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (1,373,589) (568,548) Cash flows from financing activities Repayments of long-term debt, net (266,623) (332,650) Proceeds from issuance of long-term debt 250,806 174,195 Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,247 69,954 Net cash provided by (used in) financing activities 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 3,318,787 1,441,867 Cash and cash equivalents at end of period \$ 2,318,787 1,441,867 Cash and cash equivalents at end of period \$ 2,318,787 1,341,867 Cash and cash equivalents at end of period \$ 2,318,787 1,341,867 Cash an	Net cash provided by operating activities	1,346,670		643,689
Cash received from sale of disposal group 177,995 — Acquisition of business, net of cash acquired (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (1,373,589) (568,548) Cash flows from financing activities 8 (266,623) (332,650) Proceeds from issuance of long-term debt 250,806 174,195 Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,247 69,954 Net cash provided by (used in) financing activities 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 13,201 (49,848) Cash and cash equivalents at beginning of period 2,318,787 1,441,867 Cash and cash equivalents at end of period \$ 2,331,988 \$ 1,392,019 Reconciliation of cash and cash equivalents to the balance sheet 2,284,087 1,337,090 Restricted cash in investments and assets whose use is limited 47,901 54,929	Cash flows from investing activities			
Acquisition of business, net of cash acquired (116,706) — Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (1,373,589) (568,548) Cash flows from financing activities 8 (266,623) (332,650) Proceeds from issuance of long-term debt 250,806 174,195	Capital expenditures	(1,429,805)		(997,069)
Investments in unconsolidated entities, net (8,474) (44,770) Other 3,401 473,291 Net cash used in investing activities (1,373,589) (568,548) Cash flows from financing activities \$	Cash received from sale of disposal group	177,995		_
Other Net cash used in investing activities 3,401 (1,373,589) 473,291 (568,548) Cash flows from financing activities Very cash used in investing activities Very cash grown debt, net (266,623) (332,650) (332,650) Proceeds from issuance of long-term debt (250,806) 174,195 <td>Acquisition of business, net of cash acquired</td> <td>(116,706)</td> <td></td> <td>_</td>	Acquisition of business, net of cash acquired	(116,706)		_
Net cash used in investing activities (1,373,589) (568,548) Cash flows from financing activities Repayments of long-term debt, net (266,623) (332,650) Proceeds from issuance of long-term debt 250,806 174,195 Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,247 69,954 Net cash provided by (used in) financing activities 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 40,120 (49,848) Cash and cash equivalents at beginning of period 2,318,787 1,441,867 Cash and cash equivalents at end of period \$2,318,787 \$1,337,090 Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents at end of period 2,284,087 1,337,090 Restricted cash in investments and assets whose use is limited 47,901 54,929	Investments in unconsolidated entities, net	(8,474)		(44,770)
Cash flows from financing activities Repayments of long-term debt, net (266,623) (332,650) Proceeds from issuance of long-term debt 250,806 174,195 Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,247 69,954 Net cash provided by (used in) financing activities 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 52,318,787 1,441,867 Cash and cash equivalents at end of period 2,318,787 1,441,867 Cash and cash equivalents at end of period 52,331,988 \$1,392,019 Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents 82,284,087 1,337,090 Restricted cash in investments and assets whose use is limited 47,901 54,929	Other	3,401		473,291
Repayments of long-term debt, net (266,623) (332,650) Proceeds from issuance of long-term debt 250,806 174,195 Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,247 69,954 Net cash provided by (used in) financing activities 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 313,201 (49,848) Cash and cash equivalents at beginning of period 2,318,787 1,441,867 Cash and cash equivalents at end of period \$2,331,988 \$1,392,019 Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents \$2,284,087 1,337,090 Restricted cash in investments and assets whose use is limited 47,901 54,929	Net cash used in investing activities	(1,373,589)		(568,548)
Proceeds from issuance of long-term debt Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments Net cash provided by (used in) financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents Cash and cash equivalents Restricted cash in investments and assets whose use is limited 174,195 174,195 195,310 (49,848) 13,201 (49,848) 2,318,787 1,441,867 2,331,988 \$ 1,392,019	Cash flows from financing activities			
Distribution to noncontrolling interests (53,310) (36,488) Proceeds from restricted contributions and income on investments 109,247 69,954 Net cash provided by (used in) financing activities 40,120 (124,989) Net increase (decrease) in cash and cash equivalents 2,318,787 1,441,867 Cash and cash equivalents at beginning of period 2,318,787 1,441,867 Cash and cash equivalents at end of period \$2,331,988 \$1,392,019 Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents 2,284,087 1,337,090 Restricted cash in investments and assets whose use is limited 47,901 54,929	Repayments of long-term debt, net	(266,623)		(332,650)
Proceeds from restricted contributions and income on investments Net cash provided by (used in) financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents C	Proceeds from issuance of long-term debt	250,806		174,195
Net cash provided by (used in) financing activities40,120(124,989)Net increase (decrease) in cash and cash equivalents13,201(49,848)Cash and cash equivalents at beginning of period2,318,7871,441,867Cash and cash equivalents at end of period\$ 2,331,988\$ 1,392,019Reconciliation of cash and cash equivalents to the balance sheetCash and cash equivalents2,284,0871,337,090Restricted cash in investments and assets whose use is limited47,90154,929	Distribution to noncontrolling interests	(53,310)		(36,488)
Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents Aryon Total (49,848) A,341,867 A,341,867 A,341,988 A,332,019	Proceeds from restricted contributions and income on investments	109,247		69,954
Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents Cash and cash equivalents Restricted cash in investments and assets whose use is limited 2,318,787 3,441,867 \$ 1,441,867 \$ 2,331,988 \$ 1,392,019 1,337,090 1,337,090 54,929	Net cash provided by (used in) financing activities	40,120		(124,989)
Cash and cash equivalents at end of period\$ 2,331,988\$ 1,392,019Reconciliation of cash and cash equivalents to the balance sheetCash and cash equivalents2,284,0871,337,090Restricted cash in investments and assets whose use is limited47,90154,929	Net increase (decrease) in cash and cash equivalents	13,201		(49,848)
Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents Restricted cash in investments and assets whose use is limited 2,284,087 1,337,090 47,901 54,929	Cash and cash equivalents at beginning of period	2,318,787		1,441,867
Cash and cash equivalents 2,284,087 1,337,090 Restricted cash in investments and assets whose use is limited 47,901 54,929	Cash and cash equivalents at end of period	\$ 2,331,988	\$	1,392,019
Cash and cash equivalents 2,284,087 1,337,090 Restricted cash in investments and assets whose use is limited 47,901 54,929	Reconciliation of cash and cash equivalents to the balance sheet			
	Cash and cash equivalents	2,284,087		1,337,090
\$ 2,331,988 \$ 1,392,019	Restricted cash in investments and assets whose use is limited	47,901		54,929
		\$ 2,331,988	\$	1,392,019

ADVOCATE HEALTH UTILIZATION STATISTICS AND KEY FINANCIAL RATIOS

	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023	Change	% Change
Census			-	_
Discharges	411,635	382,303	29,332	7.7 %
Observation Cases	124,801	137,433	(12,632)	(9.2)%
Total Bedded Patients	536,436	519,736	16,700	3.2 %
Inpatient Length of Stay ⁽¹⁾	5.39	5.47	(0.08)	(1.5)%
Case Mix index	1.79	1.81	(0.02)	(1.1)%
Other Volume Stats				
Inpatient Surgeries	95,362	93,262	2,100	2.3 %
Outpatient Surgeries	239,593	234,455	5,138	2.2 %
Total Surgeries	334,955	327,717	7,238	2.2 %
ED Visits	1,702,063	1,616,546	85,517	5.3 %
wRVUs ⁽¹⁾	43,749,866	39,724,246	4,025,620	10.1 %

⁽¹⁾Prior year was updated to reflect the current year measurement methodology

	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Operating Performance		
Operating margin ⁽¹⁾	3.7%	0.3%
Operating cash flow margin ⁽²⁾	8.1%	5.3%
Excess margin ⁽³⁾	9.9%	3.3%
	As of September 30, 2024	As of December 31, 2023
Leverage and Liquidity		
Debt to capitalization ⁽⁴⁾	21.7%	23.5%
Cash to debt ⁽⁵⁾	317%	283%
Days cash on hand ⁽⁶⁾	281	268

⁽¹⁾ Operating income/Total revenue

⁽²⁾⁽Operating income + Interest + Depreciation and amortization)/Total revenue

⁽³⁾ Revenue in excess of expenses/(Total revenue + Total nonoperating income, net)

⁽⁴⁾⁽Long-term debt, current portion + Long-term debt, less current portion)/(Long-term debt, current portion + Long-term debt, less current portion + Total net assets without donor restrictions)

⁽⁵⁾ Unrestricted cash and investments/(Long-term debt, current portion + Long-term debt, less current portion)

⁽⁶⁾Unrestricted cash and investments/((Total expenses - Depreciation and amortization)/days in period). The days cash on hand ratio is calculated from expenses on a trailing 12 month basis.

ADVOCATE HEALTH OTHER FINANCIAL INFORMATION

Sources of Patient Service Revenue

In the nine months ended September 30, 2024 and 2023, the composition of Advocate Health's patient service revenue by payor was as follows:

Payor Mix	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Managed care	49 %	50 %
Medicare	31 %	32 %
Medicaid	17 %	14 %
Self-pay and other	3 %	4 %
	100 %	100 %

Unrestricted cash and investments

As of September 30, 2024 and December 31, 2023, the composition of Advocate Health's unrestricted cash and investments was as follows:

	As	of September 30, 2024	As of December 31, 2023		
Cash and cash equivalents	\$	2,284,087	\$	2,260,650	
Short term investments		48,871		38,960	
Long-term investments, excluding restricted assets limited as to use		22,179,041		19,660,513	
Total unrestricted cash and investments	\$	24,511,999	\$	21,960,123	

Long-Term Debt

As of September 30, 2024 and December 31, 2023, the composition of Advocate Health's debt was as follows:

	September 30, 2024		December 31		023	
Taxable fixed bonds	\$	2,392,690	32%	\$	2,392,690	32%
Tax-exempt fixed rate bonds		1,317,880	17%		1,381,345	18%
Tax-exempt variable rate bonds		1,757,475	23%		1,824,945	24%
Put bonds		955,975	13%		914,645	12%
Commercial paper		520,000	7%		350,000	5%
Finance leases / other banks debt		571,649	8%		710,179	9%
Total Long-term debt , excluding unamortized bond premiums and bond issuance costs and commercial paper original issue discount	Ś	7,515,669	100%	Ś	7,573,804	100%
	-	- 70 = 0 70 00		-	1,010,001	



ADVOCATE AURORA HEALTH, INC.

Introduction

Advocate Aurora Health Credit Group

AAH and certain other AAH System Entities are members of the "Obligated Group" (the "AAH Obligated Group") created under a Second Amended and Restated Trust Indenture dated as of August 1, 2018 (the "AAH Master Indenture") among the Obligated Group Members identified therein and U.S. Bank Trust Company, National Association, Master Trustee. The members of the AAH Obligated Group are jointly and severally liable on any "Obligations" issued under the AAH Master Indenture. Certain of the AAH Obligated Group's affiliates are designated as "Restricted Affiliates" under the AAH Master Indenture.

Neither the Advocate JOC nor any of the AHI Enterprise Entities is a member of the AAH Obligated Group or a Restricted Affiliate as of the date of this report and, therefore, none of them have any obligation to provide for the payment of any Obligation issued under the AAH Master Indenture.

Basis of Presentation

The accompanying consolidated financial statements for AAH as of and for the three and nine months ended September 30, 2024 and 2023, have been prepared in accordance with U.S. generally accepted accounting principles, as promulgated by FASB.

ADVOCATE AURORA HEALTH, INC. CONSOLIDATED BALANCE SHEETS

		Unaudited		Audited	
	September 30, 2024		December 31, 2023		
Assets					
Current assets					
Cash and cash equivalents	\$	859,541	\$	857,599	
Assets limited as to use		172,916		179,288	
Patient accounts receivable		1,948,105		1,906,747	
Other current assets		1,483,676		1,093,683	
Total current assets		4,464,238		4,037,317	
Assets limited as to use		20,980,335		11,863,519	
Property and equipment, net		5,998,983		5,919,233	
Other assets					
Operating lease right-of-use assets		291,481		305,114	
Other noncurrent assets		656,125		872,637	
Total other assets		947,606		1,177,751	
Total assets	\$	32,391,162	\$	22,997,820	

ADVOCATE AURORA HEALTH, INC. CONSOLIDATED BALANCE SHEETS

	Unaudited	Audited		
	September 30, 2024	December 31, 2023		
Liabilities	·			
Current liabilities				
Long-term debt and commercial paper, current portion	\$ 166,378	\$ 172,759		
Long-term debt subject to short-term financing arrangements	176,605	354,720		
Operating lease liabilities, current portion	67,779	69,062		
Accrued salaries and employee benefits	1,148,588	1,245,445		
Accounts payable and other accrued liabilities	1,684,259	1,164,041		
Third-party payors payables	444,372	404,496		
Accrued insurance and claims costs, current portion	237,839	237,771		
Total current liabilities	3,925,820	3,648,294		
Noncurrent liabilities				
Long-term debt, less current portion	3,084,421	2,939,221		
Operating lease liabilities, less current portion	261,906	273,134		
Accrued insurance and claims cost, less current portion	722,325	686,643		
Obligations under swap agreements	33,377	31,681		
Due to related party	7,711,999	_		
Other noncurrent liabilities	1,174,802	1,159,793		
Total noncurrent liabilities	12,988,830	5,090,472		
Total liabilities	16,914,650	8,738,766		
Net assets				
Without donor restrictions				
Controlling interest	15,027,173	13,823,021		
Noncontrolling interests in subsidiaries	196,446	191,582		
Total net assets without donor restrictions	15,223,619	14,014,603		
With donor restrictions	252,893	244,451		
Total net assets	15,476,512	14,259,054		
Total liabilities and net assets	\$ 32,391,162	\$ 22,997,820		

ADVOCATE AURORA HEALTH, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

(in thousands)

	Unau	dited		Unau	dited	i
	ree Months Ended otember 30, 2024	Three Months Ended September 30, 2023		line Months Ended eptember 30, 2024		ine Months Ended ptember 30, 2023
Revenue						
Patient service revenue	\$ 3,542,807	\$	3,190,652	\$ 10,415,526	\$	9,578,782
Capitation revenue	296,250		302,580	893,359		915,363
Other revenue	401,169		383,886	1,181,577		1,167,648
Total revenue	4,240,226		3,877,118	12,490,462		11,661,793
Expenses						
Salaries, wages and benefits	2,395,609		2,249,304	7,094,329		6,707,037
Supplies and drugs	866,270		739,859	2,510,667		2,235,170
Purchased services and other expenses	597,640		534,290	1,673,112		1,585,961
Contracted medical services	138,036		151,394	379,084		426,882
Depreciation and amortization	137,842		153,903	417,758		461,067
Interest	30,374		31,816	91,517		94,991
Total expenses	4,165,771		3,860,566	12,166,467		11,511,108
Operating income	74,455		16,552	323,995		150,685
Nonoperating income (loss)						
Investment income (loss), net	809,914		(91,373)	1,372,948		309,300
Other nonoperating (loss) income, net	(320,691)		6,082	(450,798)		(15,504)
Total nonoperating income (loss), net	489,223		(85,291)	922,150		293,796
Revenue in excess of (less than) expenses	563,678		(68,739)	1,246,145		444,481
Less income attributable to noncontrolling interests	 (16,495)		(14,941)	 (50,850)		(44,036)
Revenue in excess of (less than) expenses - attributable to controlling interest	\$ 547,183	\$	(83,680)	\$ 1,195,295	\$	400,445

(Continued)

ADVOCATE AURORA HEALTH, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

(in thousands)

	Una	ıdited	Unau	ıdited
	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Net assets without donor restrictions, controlling interest				
Revenue in excess of (less than) expenses - attributable to controlling interest	\$ 547,183	\$ (83,680)	\$ 1,195,295	\$ 400,445
Pension-related changes other than net periodic pension costs	2,179	697	6,501	2,098
Net assets released from restrictions for purchase of property and equipment	1,027	2,423	4,399	7,058
Other, net	(864)	(1,791)	(2,043)	(3,806)
Increase (decrease) in net assets without donor restrictions, controlling interest	549,525	(82,351)	1,204,152	405,795
Net assets without donor restrictions, noncontrolling interests				
Revenues in excess of expenses	16,495	14,941	50,850	44,036
Distributions to noncontrolling interests	(10,977)	(9,101)	(45,986)	(30,353)
Increase in net assets without donor restrictions, noncontrolling interests	5,518	5,840	4,864	13,683
Net assets with donor restrictions				
Contributions	5,643	4,413	11,431	10,331
Investment income (loss), net	4,673	(834)	9,413	3,552
Net assets released from restrictions for operations	(2,668)	(2,934)	(8,183)	(8,278)
Net assets released from restrictions for purchase of property and equipment	(1,027)	(2,423)	(4,399)	(7,058)
Other, net	54	37	180	102
Increase (decrease) in net assets with donor restrictions	6,675	(1,741)	8,442	(1,351)
Increase (decrease) in net assets	561,718	(78,252)	1,217,458	418,127
Net assets at beginning of period	14,914,794	13,943,926	14,259,054	13,447,547
Net assets at end of period	\$ 15,476,512	\$ 13,865,674	\$ 15,476,512	\$ 13,865,674

(Concluded)

ADVOCATE AURORA HEALTH, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS

	Unau	dited			Unau	dited	
	ee Months Ended tember 30, 2024		ee Months Ended tember 30, 2023		ne Months Ended otember 30, 2024		ne Months Ended otember 30, 2023
Cash flows from operating activities							
Increase (decrease) in net assets	\$ 561,718	\$	(78,252)	\$	1,217,458	\$	418,127
Adjustments to reconcile change in net assets to net cash provided by operating activities:							
Depreciation, amortization and accretion	135,063		151,388		409,431		453,366
Amortization of operating lease right-of-use assets	16,088		16,678		50,390		52,468
Gain on sale of disposal group	_		_		(84,511)		_
Change in fair value of swap agreements	11,780		(12,545)		1,696		(12,836)
Pension-related changes other than net periodic pension cost	(2,179)		(697)		(6,501)		(2,098)
Net assets released from restrictions for operations	(2,668)		(2,934)		(8,183)		(8,278)
Distribution to noncontrolling interests	10,977		9,101		53,310		36,488
Distributions from unconsolidated entities	14,412		1,323		20,529		9,379
Changes in operating assets and liabilities							
Trading securities, net	(981,127)		101,890		(9,129,636)		19,440
Patient accounts receivable	113,778		(91,249)		(41,358)		(82,077)
Third-party payors receivable and payable, net	17,668		3,303		108,211		50,375
Other assets and liabilities, net	475,401		(20,790)		7,803,839		(318,930)
Net cash provided by operating activities	370,911		77,216		394,675		615,424
Cash flows from investing activities							
Capital expenditures	(180,909)		(118,796)		(503,698)		(363,072)
Cash received from sale of disposal group	_		(===,:==, _		177,995		_
Investments in unconsolidated entities, net	(360)		(392)		(3,754)		(18,113)
Other	694		(233)		210		(187)
Net cash used in investing activities	(180,575)		(119,421)		(329,247)		(381,372)
Cash flows from financing activities							
Repayments of long-term debt, net	(82,390)		(11,493)		(101,026)		(28,475)
Proceeds from issuance of long-term debt	70,006		_		70,006		_
Distribution to noncontrolling interests	(10,977)		(9,101)		(53,310)		(36,488)
Proceeds from restricted contributions and income on investments	 10,316		3,579		20,844		13,883
Net cash used in financing activities	(13,045)		(17,015)		(63,486)		(51,080)
Net increase (decrease) in cash and cash equivalents	177,291		(59,220)		1,942		182,972
Cash and cash equivalents at beginning of period	682,250		615,090		857,599		372,898
Cash and cash equivalents at end of period	\$ 859,541	\$	555,870	\$	859,541	\$	555,870
of being	 223,342		223,070	-	33,341	_	
Supplemental disclosures of noncash information							
Operating lease right-of-use assets in exchange for new operating lease liabilities	\$ 15,907	\$	30,951	\$	36,758	\$	52,821

ADVOCATE AURORA HEALTH, INC. UTILIZATION STATISTICS AND SOURCES OF REVENUE

Utilization Statistics

A summary of certain combined utilization statistics for the AAH System for the three and nine months ended September 30, 2024 and 2023 are set forth in the table below.

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Change	% Change
Historical Utilization Statistics				
Discharges	67,333	62,311	5,022	8.1 %
Observation Cases	20,444	25,573	(5,129)	(20.1)%
Patient Days	336,456	319,167	17,289	5.4 %
Hospital Outpatient Visits	1,206,609	1,139,786	66,823	5.9 %
Physician Visits	2,773,743	2,605,329	168,414	6.5 %
Home Care Visits	224,364	202,397	21,967	10.9 %
Capitated Member Lives ⁽¹⁾	215,855	223,910	(8,055)	(3.6)%
	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023	Change	% Change
Historical Utilization Statistics				
Discharges	199,336	181,753	17,583	9.7 %
Observation Cases	62,750	78,730	(15,980)	(20.3)%
Patient Days	1,011,303	947,728	63,575	6.7 %
Hospital Outpatient Visits	3,578,670	3,412,396	166,274	4.9 %
Physician Visits	8,328,921	7,838,612	490,309	6.3 %
Home Care Visits	657,282	635,287	21,995	3.5 %

⁽¹⁾ As of the date set forth in the column header

Sources of Patient Service Revenue

In the three and nine months ended September 30, 2024 and 2023, the composition of the AAH System's patient service revenue by payor was as follows:

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Payor Mix				
Managed Care	52 %	53 %	53 %	52 %
Medicare	32 %	31 %	32 %	32 %
Medicaid	13 %	14 %	13 %	13 %
Self-pay and Other	3 %	2 %	2 %	3 %
	100 %	100 %	100 %	100 %



THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY COMBINED GROUP Introduction

Atrium Health CMHA Combined Group

CMHA issues revenue bonds ("CMHA Bonds") under a Second Amended and Restated Bond Order adopted in 1997 (as amended, the "CMHA Bond Order"). CMHA and certain of its affiliates have formed an "Obligated Group" (the "CMHA Obligated Group") under the CMHA Bond Order. Members of the CMHA Obligated Group are jointly and severally liable for payment of CMHA Bonds and other obligations secured by the CMHA Bond Order ("Parity Obligations"). The CMHA Bond Order also authorizes the creation of a "Combined Group" (the "CMHA Combined Group"), which consists of the members of the CMHA Obligated Group and any affiliates designated by CMHA ("Designated Affiliates").

None of the Advocate Health JOC, the AAH System Entities, or any entities that are part of Wake Forest Baptist, Atrium Health Navicent or Atrium Health Floyd are members of the CMHA Combined Group as of the date of this report and, therefore, none of them have any obligation to provide for the payment of the CMHA Bonds or Parity Obligations.

Basis of Presentation

The accompanying consolidated financial statements and highlights reflect the financial position and results of operations of the CMHA Combined Group as of and for the nine months ended September 30, 2024 and 2023. These financial statements have been prepared in accordance with U.S. generally accepted accounting principles, as promulgated by the Governmental Accounting Standards Board ("GASB").

THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY COMBINED GROUP

Financial Highlights (in thousands)

Nine Months Ended September 30, 2024 Compared with Nine Months Ended September 30, 2023:

For the nine months ended September 30, 2024, net income was \$1,138,402, a \$917,456 increase from 2023, driven primarily by income from operations, favorable investment performance, and \$200,000 of FEMA funds included in other non-operating income net. Operating income was \$396,046 for the nine months ended September 30, 2024, which was \$302,394 above the prior year.

Total operating revenue increased 18.5% to \$7,515,567 largely due to greater hospital and medical group patient volumes and growth in retail pharmacy sales. Total operating expenses increased 13.9% to \$7,119,520, primarily due to personnel, supplies and drugs costs related to higher patient volumes along with other expense inflation.

As of September 30, 2024, days cash on hand was 304 days. Debt-to-capitalization ratio decreased from 26.5% at June 30, 2024, to 25.8% at September 30, 2024, primarily driven by net income during the current year.

THE CMHA COMBINED GROUP COMBINED BALANCE SHEETS

	Unaudited	Audited December 31, 2023		
	September 30, 2024			
Assets				
Current assets				
Cash and cash equivalents	\$ 714,863	\$ 661,959		
Short term investments	36,682	27,233		
Assets limited as to use	8,340	50,267		
Patient accounts receivable	1,145,912	1,118,037		
Other current assets	535,993	502,285		
Total current assets	2,441,790	2,359,781		
Other assets				
Assets limited as to use	6,827,729	6,258,033		
Property and equipment, net	4,793,780	4,482,299		
Operating lease right-of-use assets, net	479,609	496,898		
Other noncurrent assets	570,620	445,622		
Total other assets	12,671,738	11,682,852		
Total assets	15,113,528	14,042,633		
Deferred outflows of resources	201,283	208,945		
Total assets and deferred outflows of resources	\$ 15,314,811	\$ 14,251,578		
Liabilities				
Current liabilities				
Long-term debt, current portion	\$ 649,267	\$ 649,786		
Operating lease liabilities, current portion	73,183	73,395		
Accrued salaries and employee benefits	513,998	594,294		
Accounts payable and other accrued liabilities	763,487	822,889		
Estimated third party payer settlements	319,391	288,663		
Total current liabilities	2,319,326	2,429,027		
Noncurrent liabilities				
Long-term debt, less current portion	2,330,696	2,279,905		
Operating lease liabilities, less current portion	456,469	467,135		
Obligations under swap agreements	92,324	87,373		
Other noncurrent liabilities	885,513	893,551		
Total noncurrent liabilities	3,765,002	3,727,964		
Total liabilities	6,084,328	6,156,991		
Deferred inflows of resources	144,090	159,498		
Net position				
Net investment in capital assets	1,694,233	1,539,926		
Restricted, by donor	536,309	485,495		
Unrestricted	6,855,851	5,909,668		
Total net position	9,086,393	7,935,089		
Total liabilities and deferred inflows and net position	\$ 15,314,811	\$ 14,251,578		

THE CMHA COMBINED GROUP COMBINED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET POSITION

		Nine Months Ended September 30, 2024 September 30, 2024 \$ 5,698			
Revenue					
Patient service revenue	\$	6,588,631	\$	5,695,456	
Other revenue		926,936		649,190	
Total revenue		7,515,567		6,344,646	
Expenses					
Salaries, wages, and benefits		3,966,962		3,657,510	
Supplies and drugs		1,681,531		1,340,352	
Purchased services and other expenses		1,081,413		922,785	
Depreciation and amortization		389,615		330,347	
Total operating expenses		7,119,521		6,250,994	
Operating income		396,046		93,652	
Nonoperating income					
Interest expense		(97,442)		(98,028)	
Investment income, net		642,739		273,049	
Other nonoperating income (loss), net		197,058		(47,728)	
Total nonoperating income, net		742,355		127,293	
Excess of revenues and support over expenses and losses before contributions	\$	1,138,401	\$	220,945	
Changes in net position					
Capital and other contributions		12,903		(7,615)	
Changes in net position		1,151,304		213,330	
Net position, beginning of year	_	7,935,089		6,907,673	
Net position, end of year	\$	9,086,393	\$	7,121,003	

THE CMHA COMBINED GROUP COMBINED STATEMENTS OF CASH FLOWS

		Unaudited		
		Months Ended ember 30, 2024	Nine Months Ended September 30, 2023	
Cash flows from operating activities				
Receipts from third-party payers and patients	\$	6,591,484	\$	5,638,676
Payments to suppliers		(2,839,253)		(2,273,645)
Payments to employees		(4,036,825)		(3,753,217)
Other receipts, net		931,694		560,866
Net cash provided by operating activities		647,100		172,680
Cash flows from financing activities				
Cash flows from noncapital financing activities				
Proceeds from the issuance of commercial paper		350,000		_
Retirements of commercial paper		(250,000)		_
Commitment to academic endowment fund		_		(47,000)
Other activities		185,483		(17,442)
Net cash provided by (used in) noncapital financing activities		285,483		(64,442)
Cash flows from capital and related financing activities				
Capital expenditures		(724,478)		(481,198
Interest payments on short- and long-term debt		(109,257)		(104,789)
Repayments of long-term debt, net		(44,820)		(212,367)
Proceeds from issuance of long-term debt		_		174,195
Contributions restricted for building and equipment purchases		(2,184)		(10,451)
Other contributions		13,627		3,383
Net cash used in capital and related financing activities		(867,112)		(631,227)
Cash flows from investing activities				
Investment earnings		14,700		10,676
Withdrawals from assets limited as to use		6,604,090		456,744
Contributions to assets limited as to use		(6,535,191)		(84,898
Acquisition of business		(121,902)		. –
Purchase of equity method investments		(4,720)		(27,657
Net cash (used in) provided by investing activities		(43,023)		354,865
Net increase (decrease) in cash, cash equivalents and restricted cash		22,448		(168,124
Cash and cash equivalents				
Beginning of year		693,166		486,680
End of period	\$	715,614	\$	318,556
Reconciliation of cash and cash equivalents to the balance sheet				
Cash and cash equivalents		714,863		287,378
Restricted cash in investments and assets whose use is limited		751		31,178
Total cash, cash equivalents and restricted cash	\$	715,614	\$	318,556
Reconciliation of operating income to net cash used in operating activities				
Operating income	\$	396,046	\$	93,652
Adjustments to reconcile operating income to net cash used in operating activities				
Depreciation and amortization		389,615		330,347
Increase in patient accounts receivable, net		(27,875)		(60,771)
Decrease (increase) in other current assets		4,801		(87,218
Decrease (increase) in other noncurrent assets		10,008		(75,318
Decrease in accounts payable and other accrued liabilities		(121,858)		(20,377
Decrease in other noncurrent liabilities		(34,365)		(11,626
Increase in estimated third party payer settlements		30,728		3,991
Net cash provided by operating activities	Ś	647,100	\$	172,680

THE CMHA COMBINED GROUP UTILIZATION STATISTICS

	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023 Change		% Change
Medical Group				_
Practice locations	565	542	23	4.2 %
Total Physicians	1,942	1,873	69	3.7 %
Patient visits (including faculty) ⁽¹⁾	5,057,337	4,754,312	303,025	6.4 %
Total Acute Care Facilities				
Adjusted patient days (excluding newborn)	1,582,366	1,453,843	128,523	8.8 %
Adjusted discharges (excluding newborn)	181,408	254,290	(72,882)	(28.7)%
Surgical Procedures	80,474	76,793	3,681	4.8 %

 $^{^{(1)}}$ Prior year visits updated to reflect the current year measurement methodology.



ATRIUM HEALTH WAKE FOREST BAPTIST

Introduction

Atrium Health Wake Forest Baptist Combined Group

Atrium Health Wake Forest Baptist is an integrated clinical, research and academic enterprise operated by Wake Forest University Baptist Medical Center, a North Carolina nonprofit corporation ("WFUBMC"), which is a joint operating company that was established by Wake Forest University, a North Carolina nonprofit corporation ("WFU"), and North Carolina Baptist Hospital, a North Carolina nonprofit corporation ("NCBH"). Wake Forest University Health Sciences ("WFUHS") is a wholly-owned affiliate of WFU that owns all of the assets of and operates Wake Forest University School of Medicine and is part of Atrium Health Wake Forest Baptist.

WFUBMC, NCBH and WFUHS are the members of the "Obligated Group" (the "WFB Obligated Group") created under a Master Trust Indenture, dated as of March 1, 2010 (as supplemented and amended, the "WFB Master Indenture"), between NCBH and The Bank of New York Mellon Trust Company, N.A., as master trustee. The members of the WFB Obligated Group are jointly and severally liable on any "Obligations" issued under the WFB Master Indenture. The WFB Master Indenture authorizes the creation of a "Combined Group" (the "WFB Combined Group"), which consists of the members of the WFB Obligated Group and all "Designated Members." Wake Forest University is not a member of the WFB Obligated Group or a part of Wake Forest Baptist and is not directly or indirectly obligated to pay amounts due with respect to Obligations issued under the WFB Master Indenture.

None of the Advocate Health JOC, the AAH System Entities or CMHA or any of its affiliates are members of the WFB Combined Group as of the date of this report and, therefore, none of them have any obligation to provide for the payment of any Obligation issued under the WFB Master Indenture.

Basis of Presentation

The accompanying combined financial statements reflect the financial position and results of operations of Atrium Health Wake Forest Baptist as of and for the nine months ended September 30, 2024 and 2023. These financial statements have been prepared in accordance with U.S. generally accepted accounting principles, as promulgated by FASB.

ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED BALANCE SHEETS

	Unaudited	Audited		
	September 30, 2024	December 31, 2023		
Assets				
Current assets				
Cash and cash equivalents	\$ 386,781	\$ 443,244		
Patient accounts receivable	513,068	480,560		
Other current assets	322,345	314,603		
Total current assets	1,222,194	1,238,407		
Other assets				
Assets limited as to use	2,305,637	2,112,309		
Property and equipment, net	1,462,976	1,318,795		
Operating lease right-of-use assets	164,007	171,857		
Other noncurrent assets	181,491	206,757		
Total other assets	4,114,111	3,809,718		
Total assets	\$ 5,336,305	\$ 5,048,125		
Liabilities				
Current liabilities				
Long-term debt, current portion	\$ 53,447	\$ 53,201		
Operating lease liabilities, current portion	43,016	41,506		
Accrued salaries and employee benefits	430,676	444,133		
Accounts payable and other accrued liabilities	388,173	337,554		
Third-party payors payables	116,585	105,590		
Total current liabilities	1,031,897	981,984		
Noncurrent liabilities				
Long-term debt, less current portion	791,969	815,626		
Operating lease liabilities, less current portion	127,989	137,401		
Obligations under swap agreements	1,051	1,058		
Other noncurrent liabilities	201,789	231,575		
Total noncurrent liabilities	1,122,798	1,185,660		
Total liabilities	2,154,695	2,167,644		
Net assets				
Without donor restrictions				
Controlling interest	2,666,081	2,403,236		
Noncontrolling interests in subsidiaries	11,011	10,742		
Total net assets without donor restrictions	2,677,092	2,413,978		
With donor restrictions	504,518	466,503		
Total net assets	3,181,610	2,880,481		
Total liabilities and net assets	\$ 5,336,305	\$ 5,048,125		

ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

		Unau	dited	
		Months Ended ember 30, 2024		Months Ended mber 30, 2023
Revenue	\$ 3.123.835 \$			
Patient service revenue	\$	3,123,835	\$	2,757,222
Other revenue		880,813		755,480
Total revenue		4,004,648		3,512,702
Expenses				
Salaries, wages and benefits		2,158,277		2,133,202
Supplies and drugs		983,873		863,862
Purchased services and other expenses		612,681		430,868
Depreciation and amortization		118,775		117,031
Interest		23,447		25,145
Total expenses		3,897,053		3,570,108
Operating income (loss)		107,595		(57,406)
Nonoperating income				
Investment income, net		161,527		29,831
Other nonoperating loss, net		(5,592)		(24)
Total nonoperating income, net		155,935		29,807
Revenue in excess of (less than) expenses		263,530		(27,599)
Less income attributable to noncontrolling interests		(269)		(462)
Revenue in excess of (less than) expenses - attributable to controlling interest	\$	263,261	\$	(28,061)

ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

	Unau	dited	
	 Months Ended mber 30, 2024		Months Ended mber 30, 2023
Net assets without donor restrictions, controlling interest			
Revenue in excess of (less than) expenses - attributable to controlling interest	\$ 263,261	\$	(28,061)
Pension-related changes other than net periodic pension costs	(416)		(568)
Increase (decrease) in net assets without donor restrictions, controlling interest	262,845		(28,629)
Net assets without donor restrictions, noncontrolling interests			
Revenues in excess of expenses - attributable to noncontrolling interests	269		462
Increase in net assets without donor restrictions, noncontrolling interests	269		462
Net assets with donor restrictions			
Contributions	87,618		66,746
Investment income, net	13,322		5,933
Net assets released from restrictions	(68,635)		(48,846)
Other, net	 5,710		(271)
Increase in net assets with donor restrictions	38,015		23,562
Increase (decrease) in net assets	301,129		(4,605)
Net assets at beginning of period	2,880,481		2,574,394
Net assets at end of period	\$ 3,181,610	\$	2,569,789

ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED STATEMENTS OF CASH FLOWS

	Unaudited				
		Nonths Ended mber 30, 2024		Nonths Ended mber 30, 2023	
Cash flows from operating activities					
Increase (decrease) in net assets	\$	301,129	\$	(4,605)	
Adjustments to reconcile change in net assets to net cash provided by operating activities:					
Depreciation and amortization		117,948		116,203	
Amortization of operating lease right-of-use assets		31,027		30,804	
Change in fair value of swap agreements		(7)		(581)	
Pension-related changes other than net periodic pension cost		416		568	
Proceeds from restricted contributions		(8,721)		(3,570)	
Changes in operating assets and liabilities					
Trading securities, net		(173,108)		109,007	
Patient accounts receivable		(32,508)		(43,160)	
Third-party payors payables		10,995		4,226	
Other assets and liabilities, net		(13,461)		(100,095)	
Net cash provided by operating activities		233,710		108,797	
Cash flows from investing activities					
Purchases of property and equipment		(256,097)		(129,235)	
Proceeds from sale of property and equipment		7			
Net cash used in investing activities		(256,090)		(129,235)	
Cash flows from financing activities					
Repayments of long-term debt, net		(103,384)		(59,846)	
Proceeds from issuance of long-term debt		80,800			
Contributions restricted for long-term investment		8,721		3,570	
Net cash used in financing activities		(13,863)		(56,276)	
Net decrease increase in cash, cash equivalents and restricted cash		(36,243)		(76,714)	
Cash, cash equivalents and restricted cash at beginning of period		470,174		323,502	
Cash, cash equivalents and restricted cash at end of period	\$	433,931	\$	246,788	
Reconciliation of cash, cash equivalents and restricted cash to the balance sheet					
Cash and cash equivalents		386,781		223,037	
Restricted cash in assets limited as to use		47,150		23,751	
Total cash, cash equivalents and restricted cash	\$	433,931	\$	246,788	
	<u> </u>	,	$\dot{-}$	-,	

ATRIUM HEALTH WAKE FOREST BAPTIST COMBINING BALANCE SHEET INFORMATION

	September 30, 2024							
		rium Health /ake Forest Baptist	Forest Non-Designated		Eliminations		Atrium Health Wake Forest Baptist Combined Group	
Assets								
Current assets								
Cash and cash equivalents	\$	386,781	\$	(29,873)	\$	_	\$	356,908
Patient accounts receivable		513,068		(22,051)		_		491,017
Other current assets		322,345		174,623		(218,659)		278,309
Total current assets		1,222,194		122,699		(218,659)		1,126,234
Other assets								
Assets limited as to use		2,305,637		(141,150)		_		2,164,487
Property and equipment, net		1,462,976		(103,461)		_		1,359,515
Operating lease right-of-use assets		164,007		(50,413)		_		113,594
Other noncurrent assets		181,491		(88,616)		(59,122)		33,753
Total other assets		4,114,111		(383,640)		(59,122)		3,671,349
Total assets	\$	5,336,305	\$	(260,941)	\$	(277,781)	\$	4,797,583
Liabilities								
Current liabilities								
Long-term debt, current portion	\$	53,447	\$	(993)	\$	_	\$	52,454
Operating lease liabilities, current portion		43,016		(11,838)		_		31,178
Accrued salaries and employee benefits		430,676		(13,015)		_		417,661
Accounts payable and other accrued liabilities		388,173		(15,089)		(218,659)		154,425
Third-party payors payables		116,585		(32,916)				83,669
Total current liabilities		1,031,897		(73,851)		(218,659)		739,387
Noncurrent liabilities								
Long-term debt, less current portion		791,969		(21,584)		_		770,385
Operating lease liabilities, less current portion		127,989		(40,607)		_		87,382
Obligations under swap agreements		1,051		_		_		1,051
Other noncurrent liabilities		201,789		(1,634)		_		200,155
Total noncurrent liabilities		1,122,798		(63,825)		_		1,058,973
Total liabilities		2,154,695		(137,676)		(218,659)		1,798,360
Net assets								
Without donor restrictions								
Controlling interest		2,666,081		(123,064)		(49,125)		2,493,892
Noncontrolling interests in subsidiaries		11,011				(9,997)		1,014
Total net assets without donor restrictions		2,677,092		(123,064)		(59,122)		2,494,906
With donor restrictions		504,518		(201)		_		504,317
Total net assets		3,181,610		(123,265)		(59,122)		2,999,223
Total liabilities and net assets	\$	5,336,305	\$	(260,941)	\$	(277,781)	\$	4,797,583
								•

ATRIUM HEALTH WAKE FOREST BAPTIST COMBINING STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

(in thousands)

	Nine Months Ended September 30, 2024								
		Atrium Health Wake Forest Baptist		Non-Designated Entities		Eliminations		Atrium Health Wake Forest Baptist Combined Group	
Revenue									
Patient service revenue	\$	3,123,835	\$	(211,782)	\$	-	\$	2,912,053	
Other revenue		880,813		(45,443)				835,370	
Total revenue		4,004,648		(257,225)		_		3,747,423	
Expenses									
Salaries, wages and benefits		2,158,277		(158,466)		_		1,999,811	
Supplies and drugs		983,873		(44,102)		_		939,771	
Purchased services and other expenses		612,681		(68,863)		_		543,818	
Depreciation and amortization		118,775		(13,155)		_		105,620	
Interest		23,447		(690)				22,757	
Total expenses		3,897,053		(285,276)				3,611,777	
Operating income		107,595		28,051		_		135,646	
Nonoperating income (loss)									
Investment income (loss), net		161,527		(13,984)		-		147,543	
Other nonoperating (loss) income, net		(5,592)		821		(43,818)		(48,589)	
Total nonoperating income (loss), net		155,935		(13,163)		(43,818)		98,954	
Revenue in excess of (less than) expenses		263,530		14,888		(43,818)		234,600	
Less income attributable to noncontrolling interests		(269)				120		(149)	
Revenue in excess of (less than) expenses - attributable to controlling interest	\$	263,261	\$	14,888	\$	(43,698)	\$	234,451	

(Continued)

ATRIUM HEALTH WAKE FOREST BAPTIST COMBINING STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

	Nine Months Ended September 30, 2024							
	Atrium Health Wake Forest Non-Designated Baptist Entities		Eli	minations	Atrium Health Wake Forest Baptist Combined Group			
Net assets without donor restrictions, controlling interest								
Revenue in excess of (less than) expenses - attributable to controlling interest	\$	263,261	\$	14,888	\$	(43,698)	\$	234,451
Pension-related changes other than net periodic pension costs		(416)				_		(416)
Increase (decrease) in net assets without donor restrictions, controlling interest		262,845		14,888		(43,698)		234,035
Net assets without donor restrictions, noncontrolling interests								
Revenues in excess of (less than) expenses - attributable to noncontrolling interests		269		_		(120)		149
Increase (decrease) in net assets without donor restrictions, noncontrolling interests		269		_		(120)		149
Net assets with donor restrictions								
Contributions		87,618		(334)		_		87,284
Investment income, net		13,322		_		_		13,322
Net assets released from restrictions		(68,635)		145		_		(68,490)
Other, net		5,710				_		5,710
Increase (decrease) in net assets with donor restrictions		38,015		(189)				37,826
Increase (decrease) in net assets		301,129		14,699		(43,818)		272,010
Net assets at beginning of period		2,880,481		(137,964)		(15,304)		2,727,213
Net assets at end of period	\$	3,181,610	\$	(123,265)	\$	(59,122)	\$	2,999,223

ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED GROUP UTILIZATION STATISTICS

	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023	Change	% Change
Case Mix Adjusted Equivalent Discharges	239,381	232,307	7,074	3.0 %
Patient Days	264,647	257,166	7,481	2.9 %
Inpatient Admissions	50,329	47,841	2,488	5.2 %
Average Length of Stay	5.26	5.38	(0.12)	(2.2)%
Average Length of Stay (Case Mix Adjusted)	2.82	2.77	0.05	1.8 %
Inpatient Operating Room Cases	14,458	14,271	187	1.3 %
Outpatient Operating Room Cases	32,953	33,226	(273)	(0.8)%
Total Operating Room Cases	47,411	47,497	(86)	(0.2)%
Emergency Department Visits	161,901	161,621	280	0.2 %
Case Mix Index (all payors using Medicare weights)	1.8621	1.9382	(0.0761)	(3.9)%
RVUs	8,021,476	7,539,389	482,087	6.4 %
Outpatient Visits	1,568,990	1,540,848	28,142	1.8 %